Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$6.05 USD
0.00 (0.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $6.05 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.05 USD
0.00 (0.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $6.05 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
by Zacks Equity Research
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
by Zacks Equity Research
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.
Wave Life Sciences Plunges After DMD Study Data Readout
by Zacks Equity Research
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
by Zacks Equity Research
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Sarepta Announces Agreement With Lysogene for Gene Therapy
by Zacks Equity Research
Sarepta Therapeutics (SRPT) signs license agreement with France-based Lysogene to boost its gene therapy portfolio.
Pfizer Discontinues Studies on DMD Candidate Domagrozumab
by Zacks Equity Research
Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
by Zacks Equity Research
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
by Indrajit Bandyopadhyay
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
by Zacks Equity Research
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Sarepta's Stock Soars on Encouraging Gene Therapy Results
by Zacks Equity Research
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.
Company News For Jun 19, 2018
by Zacks Equity Research
Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA
Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug
by Zacks Equity Research
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.